On that, if I may, in Germany they did institute a law on negotiations about four or five years ago. In the German culture, they need to have access. If a physician prescribes a drug, they are entitled to get that drug. For one year after the launch of that drug, it's whatever price the manufacturer has. Then the assessment by their agency—similar to us—takes place, and then they set a price. When the company doesn't like that price because of international reference pricing, there have been a number of cases where the company has decided not to sell their drug in Germany because of that.
In Canada, I think the public plans...because of the pan-Canadian Pharmaceutical Alliance, we've taken good steps to try and manage the pricing. Where the situation is difficult is with the private payers. They don't have a negotiation strength with the manufacturers. They simply take whatever price is offered to them by the manufacturer.
For the public drug plans, they have the information we present to them, so they go into the negotiations from a position of strength. They know what a cost-effective price is and they have a sensitivity analysis of where that price point would demonstrate cost effectiveness. The private payers have access to our information publicly, but they're not able to do those good negotiations with the manufacturers at this point.